Overview

Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study assess the safety/tolerability, PK/PD of LCZ696 in patients with stable heart failure.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696
Sacubitril and valsartan sodium hydrate drug combination